Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study)

This randomized, double-blind, placebo-controlled Phase II study evaluates whether daily subcutaneous tesamorelin (a growth hormone-releasing hormone analog) reduces liver fat in adults with fatty liver disease. Participants receive tesamorelin or matching placebo for 52 weeks, with standardized lifestyle counseling in both groups. Liver fat is quantified by MRI-proton density fat fraction (MRI-PDFF). Key safety monitoring includes glucose metrics and IGF-1.

NCT Number	NCT07481734
Lead Sponsor	Hudson Biotech
Conditions	Metabolic Associated Steatotic Liver Disease, Nonalcoholic Steatohepatitis, Hepatic Steatosis
Enrollment	120 participants
Start Date	2026-02-02
Primary Completion	2027-02-14 (estimated)
Study Completion	2028-02-17 (estimated)
Updated on ClinicalTrials.gov	2026-03-19